ライフサイエンスコーパス: Hodgkin's lymphoma

1 ed (2 with disease progression and none from Hodgkin's lymphoma).

2 avitations were significantly more common in Hodgkin's lymphoma.

3 veral human lymphoid malignancies, including Hodgkin's lymphoma.

4 atment in patients with previously untreated Hodgkin's lymphoma.

5 hat is closely related to nodular sclerosing Hodgkin's lymphoma.

6 n's lymphoma, and 0.2 (95% CI, 0.07-4.2) for Hodgkin's lymphoma.

7 e of differentiation between sarcoidosis and Hodgkin's lymphoma.

8 ine therapy in treatment-naive patients with Hodgkin's lymphoma.

9 ile, in patients with relapsed or refractory Hodgkin's lymphoma.

10 e useful in differentiating sarcoidosis from Hodgkin's lymphoma.

11 th intranodal calcifications more often than Hodgkin's lymphoma.

12 treated patients with relapsed or refractory Hodgkin's lymphoma.

13 atients with treatment naive, advanced stage Hodgkin's lymphoma.

14 s involved more often in sarcoidosis than in Hodgkin's lymphoma.

15 xpressed in B-cell malignancies, such as non-Hodgkin's lymphoma.

16 red for GC formation and associated with non-Hodgkin's lymphoma.

17 ancer, and 2.31 (95% CI: 1.48, 3.61) for non-Hodgkin's lymphoma.

18 y, anus, head and neck, and skin, as well as Hodgkin's lymphoma.

19 ver 200 patient tissues, including NSCLC and Hodgkin's Lymphoma.

20 toxicity in patients with relapsed classical Hodgkin's lymphoma.

21 rapeutic effect in patients with indolent or Hodgkin's lymphoma.

22 ectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma.

23 hibitor, in patients with relapsed classical Hodgkin's lymphoma.

24 l eludes most patients with leukemia and non-Hodgkin's lymphoma.

25 ent for first-line therapy of follicular non-Hodgkin's lymphoma.

26 ymphomas and included both Hodgkin's and non-Hodgkin's lymphoma.

27 erize a class of low-abundant tumor cells in Hodgkin's lymphoma.

28 ly anaplastic large-cell lymphoma (ALCL) and Hodgkin's lymphoma.

29 g alkylating agent score, and a diagnosis of Hodgkin's lymphoma.

30 ide an optimal ADC for the treatment for non-Hodgkin's lymphoma.

31 cancers, including Kaposi's sarcoma and non-Hodgkin's lymphoma.

32 ated for all malignant lymphomas and for non-Hodgkin's lymphoma.

33 therapeutic target for high-grade B cell non-Hodgkin's lymphoma.

34 irculating tumor cells in a patient with non-Hodgkin's lymphoma.

35 ated in some malignant cancer cell lines and Hodgkin's lymphoma.

36 , colorectal, and gynecologic cancer and non-Hodgkin's lymphoma.

37 in the treatment of multiple myeloma and non-Hodgkin's lymphoma.

38 r improving the outcome in patients with non-Hodgkin's lymphoma.

39 odies is an effective therapy for B-cell non-Hodgkin's lymphoma.

40 of Jordan, died after a long battle with non-Hodgkin's lymphoma.

41 een the use of NNRTIs and the development of Hodgkin's lymphoma.

42 ults in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

43 tly being defined for both Hodgkin's and non-Hodgkin's lymphoma.

44 phoma (DLBCL) is the most common form of non-Hodgkin's lymphoma.

45 on-Hodgkin's lymphoma and, more recently, in Hodgkin's lymphoma.

46 nced solid tumors or relapsed/refractory non-Hodgkin's lymphoma.

47 lop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma.

48 proven efficacy in multiple myeloma and non-Hodgkin's lymphoma.

49 o guide treatment for patients with advanced Hodgkin's lymphoma.

50 HD14 trial), and advanced-stage (HD15 trial) Hodgkin's lymphoma.

51 iagnosis of pathologically confirmed primary Hodgkin's lymphoma.

52 s improved the outcome for patients with non-Hodgkin's lymphoma.

53 r of poor prognosis in aggressive B cell non-Hodgkin's lymphoma.

54 haryngeal carcinoma, Burkitt's lymphoma, and Hodgkin's lymphoma.

55 cond cancer remains crucial for survivors of Hodgkin's lymphoma.

56 years after the initiation of treatment for Hodgkin's lymphoma.

57 sed by stage 2A, grade I, nodular sclerosing Hodgkin's lymphoma.

58 ously heavily treated relapsed or refractory Hodgkin's lymphoma.

59 patients with relapsed or primary refractory Hodgkin's lymphoma.

60 sion in patients with relapsed or refractory Hodgkin's lymphoma.

61 CT) for patients with relapsed or refractory Hodgkin's lymphoma.

62 combination of a non-Hodgkin lymphoma and a Hodgkin's lymphoma.

63 atients with previously treated indolent non-Hodgkin's lymphomas.

64 d cancers such as multiple sclerosis and non-Hodgkin's lymphomas.

65 hat distinguish them from other types of non-Hodgkin's lymphomas.

66 L) and a number of histologies of B-cell non-Hodgkin's lymphomas.

67 rable prognosis compared with the B-cell non-Hodgkin's lymphomas.

68 line treatment in patients with indolent non-Hodgkin's lymphomas.

69 ll lymphoma (MCL) as compared with other non-Hodgkin's lymphomas.

70 lymphocytic leukemia and indolent B cell non-Hodgkin's lymphomas.

71 Cancers included: Hodgkin's lymphoma (13), non-Hodgkin's lymphoma (one), p

72 b encephalitis (eight ovarian teratomas, one Hodgkin's lymphoma), 18 (32.1%) a Possible NMDAR-Ab ence

73 In non-Hodgkin's lymphoma, 18F-FDG uptake in tumors typically d

74 ion occurred in 10.4% of the cases including Hodgkin's lymphoma (3%), B-cell lymphoma (1.4%), unclass

75 reast (19%), lung (6%), pancreatic (6%), non-Hodgkin's lymphoma (6%), melanoma (6%), prostate (4%), a

76 , 18.13-20.03], liver [3.21, 3.02-3.41], and Hodgkin's lymphoma [7.70, 7.20-8.23]), and some virus-un

77 3%, respectively), of chest radiotherapy for Hodgkin's lymphoma (87%, 79%, and 61%, respectively), an

78 ed risk of primary cerebral and systemic non-Hodgkin's lymphoma, a stable or slightly increased risk

79 Among patients with Hodgkin's lymphoma, ABVD therapy alone, as compared with

80 Hodgkin's lymphoma accounts for about 10% of all lymphom

81 tion of patients with relapsed or refractory Hodgkin's lymphoma achieving PET-negativity, and therefo

82 antly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell targ

83 lumab monotherapy in patients with classical Hodgkin's lymphoma after failure of both autologous stem

84 durable antitumor responses in patients with Hodgkin's lymphoma after hematopoietic stem-cell transpl

85 tients with relapsed or refractory classical Hodgkin's lymphoma aged 18 years or older were treated w

86 In classic Hodgkin's lymphoma, alterations in chromosome 9p24.1 inc

87 eported in renal cancer, bladder cancer, and Hodgkin's lymphoma among many others.

88 s had newly diagnosed, histologically proven Hodgkin's lymphoma, an Eastern Cooperative Oncology Grou

89 Hodgkin's lymphoma and anaplastic large-cell lymphoma ar

90 CD30-positive hematologic cancers, primarily Hodgkin's lymphoma and anaplastic large-cell lymphoma.

91 treated patients with relapsed or refractory Hodgkin's lymphoma and anaplastic large-T-cell lymphoma.

92 ncidence of transformation to high-grade non-Hodgkin's lymphoma and development of therapy-related my

93 benefit in the post-treatment evaluation of Hodgkin's lymphoma and diffuse large B-cell lymphoma; ho

94 iovascular health conditions in survivors of Hodgkin's lymphoma and general population controls.

95 er understanding of fatigue in patients with Hodgkin's lymphoma and Hodgkin's lymphoma survivors and

96 Three patients presented with EBV-associated Hodgkin's lymphoma and hypogammaglobulinemia; one also h

97 lony stimulating factor in patients with non-Hodgkin's lymphoma and multiple myeloma.

98 is unclear whether patients with early-stage Hodgkin's lymphoma and negative findings on positron-emi

99 ess, patients in this study with early-stage Hodgkin's lymphoma and negative PET findings after three

100 gned 65 patients to treatment (64 [98%] with Hodgkin's lymphoma and one [2%] with anaplastic large-T-

101 dioimmunotherapy for orbital and adnexal non-Hodgkin's lymphoma and other lymphoproliferative disorde

102 In patients with Hodgkin's lymphoma and peripheral T-cell lymphoma, treat

103 data gives insight into the dynamics of Non-Hodgkin's lymphoma and provides a platform to generate c

104 tudies have established the link between non-Hodgkin's lymphoma and SLE.

105 dvanced into phase I clinical studies in non-Hodgkin's lymphoma and solid cancers.

106 to assess biochemical changes induced by non-Hodgkin's lymphoma and subcutaneous melanoma.

107 ng to having nodular, lymphocyte-predominant Hodgkin's lymphoma and thus 45 patients received treatme

108 widely appreciated in aggressive B-cell non-Hodgkin's lymphoma and, more recently, in Hodgkin's lymp

109 xpression levels on the vast majority of non-Hodgkin's lymphomas and some leukemias.

110 cer suppression that is often deleted in non-Hodgkin's lymphomas and various epithelial tumors.

111 3.2) for PTLD, 1.8 (95% CI, 1.4-2.4) for non-Hodgkin's lymphoma, and 0.2 (95% CI, 0.07-4.2) for Hodgk

112 homa, a stable or slightly increased risk of Hodgkin's lymphoma, and improved prognosis for those who

113 stable disease, including those with DLBCL, Hodgkin's lymphoma, and multiple myeloma.

114 treatment of acute lymphocytic leukemia, non-Hodgkin's lymphoma, and osteosarcoma.

115 allogeneic transplantation in patients with Hodgkin's lymphoma, and relapse has now become the major

116 ng cancer (aOR, 2.18; 95% CI, 1.80 to 2.64), Hodgkin's lymphoma (aOR, 1.77; 95% CI, 1.33 to 2.37), pr

117 Survivors of Hodgkin's lymphoma are at increased risk for treatment-r

118 Survivors of pediatric Hodgkin's lymphoma are at risk for radiation therapy-ind

119 Malignant cells of classical Hodgkin's lymphoma are characterised by genetic alterati

120 ughly 70-80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and

121 Most human B-cell non-Hodgkin's lymphomas arise from germinal centers.

122 as been a useful medication for managing non-Hodgkin's lymphoma as well as autoimmune diseases charac

123 c agent used in treatment of gliomas and non-Hodgkin's lymphomas, as a multitype age-dependent branch

124 omas (PTCL) are a heterogeneous group of non-Hodgkin's lymphomas associated with an unfavorable progn

125 ined allorecognition of an HLA-A2-restricted Hodgkin's lymphoma-associated antigen and were able to i

126 -old woman treated with mantle radiation for Hodgkin's lymphoma at 16 years of age, and on the basis

127 tle-cell lymphoma (MCL), indolent B-cell non-Hodgkin's lymphomas (B-NHL), and CLL to determine the ac

128 EBV-induced B cell proliferations including Hodgkin's lymphoma because of a deficiency in CD70, the

129 ated in micro-dissected malignant cells from Hodgkin's lymphoma biopsies when compared to their norma

130 l of Europe did not change significantly for Hodgkin's lymphoma, Burkitt's lymphoma, CNS tumours, neu

131 ne disorders and is strongly associated with Hodgkin's lymphoma, Burkitt's lymphoma, diffuse large B-

132 ax5 positive) can be used to not only detect Hodgkin's lymphoma but also differentiate it from benign

133 for approximately 40% of newly diagnosed non-Hodgkin's lymphoma cases globally.

134 s at the EBV vIL-10 locus exclusively in the Hodgkin's lymphoma cell line, Hs 611.T, the expression o

135 alidated with western blotting in the HDLM-2 Hodgkin's lymphoma cell line.

136 omas (CTCLs) are a heterogenous group of non-Hodgkin's lymphomas characterized by atypical, skin-homi

137 as (CTCLs) form a heterogeneous group of non-Hodgkin's lymphomas characterized by only poor prognosis

138 is associated with a high risk of classical Hodgkin's lymphoma (cHL) in the combined antiretroviral

139 o identify susceptibility loci for classical Hodgkin's lymphoma (cHL), we conducted a genome-wide ass

140 ion in patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate risk

141 Radiation Therapy in Treating Patients With Hodgkin's Lymphoma) compared doxorubicin, bleomycin, vin

142 B-cell non-Hodgkin's lymphoma comprises biologically and clinically

143 Management of Hodgkin's lymphoma continues to develop.

144 dependently associated with C. glabrata, non-Hodgkin's lymphoma, cytomegalovirus (CMV) antigenemia, d

145 a (BL) is a highly malignant, aggressive non-Hodgkin's lymphoma derived from germinal center B cells.

146 Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin's lymphomas derived from T cells that home to an

147 offer clinical benefit for patients with non-Hodgkin's lymphoma, especially for those with aggressive

148 The prognosis of patients with relapsed Hodgkin's lymphoma, especially those who relapse after s

149 Group (CCG) opened a trial for patients with Hodgkin's lymphoma evaluating whether low-dose involved-

150 f 62 patients died during the trial (24 from Hodgkin's lymphoma), for a 3-year progression-free survi

151 early-stage unfavourable, and advanced-stage Hodgkin's lymphoma from the HD13, HD14, and HD15 trials,

152 Administration approval of rituximab for non-Hodgkin's lymphoma has improved standard chemotherapeuti

153 s decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these c

154 Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.

155 The extreme pathological diversity of non-Hodgkin's lymphomas has made their accurate histological

156 Black children with Hodgkin's lymphoma have lower event-free survival than w

157 is a growing population of survivors of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL)

158 poietic stem-cell transplantation (aHCT) for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL)

159 Survivors of childhood Hodgkin's lymphoma (HL) are at risk for second malignant

160 Limited-stage Hodgkin's lymphoma (HL) has been treated with radiation

161 Hodgkin's lymphoma (HL) has no standard of care for pati

162 t genome-wide association studies (GWASs) of Hodgkin's lymphoma (HL) have identified susceptibility l

163 nd primary malignancy after chemotherapy for Hodgkin's lymphoma (HL) in a much larger cohort than any

164 among women receiving chest radiotherapy for Hodgkin's lymphoma (HL) is well-established.

165 PURPOSE Children with Hodgkin's lymphoma (HL) routinely undergo surveillance c

166 ace on clinical outcomes among children with Hodgkin's lymphoma (HL) treated with contemporary therap

167 Survivors of Hodgkin's lymphoma (HL) who received mediastinal irradia

168 ite significant advances in the treatment of Hodgkin's lymphoma (HL), a significant proportion of pat

169 KDM6B may contribute to the pathogenesis of Hodgkin's Lymphoma (HL), an Epstein-Barr virus (EBV) ass

170 nesis of chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL

171 In patients with early unfavorable Hodgkin's lymphoma (HL), combined modality treatment wit

172 Despite relative success of therapy for Hodgkin's lymphoma (HL), novel therapeutic agents are ne

173 st widely used risk stratification index for Hodgkin's lymphoma (HL).

174 (GC) B-cell-derived malignancies, including Hodgkin's lymphoma (HL).

175 suggested a relationship between smoking and Hodgkin's lymphoma (HL).

176 (AIs) are associated with elevated risk for Hodgkin's lymphoma (HL); however, information on the int

177 nce interval [CI], 1.92-5.11; P<0.0001), non-Hodgkin's lymphoma (HR, 2.37; CI, 1.53-3.68; P=0.0001),

178 in's lymphoma (HR, 3.2; 95% CI, 2.8 to 3.7), Hodgkin's lymphoma (HR, 3.0; 95% CI, 1.7 to 5.3), lip ca

179 onfidence interval (95% CI), 4.7 to 18), non-Hodgkin's lymphoma (HR, 3.2; 95% CI, 2.8 to 3.7), Hodgki

180 plasms (HR, 2.26; 95% CI, 1.24 to 4.12), non-Hodgkin's lymphomas (HR, 1.81; 95% CI, 1.12 to 2.93), an

181 tive in controlling stage IA or IIA nonbulky Hodgkin's lymphoma in 90% of patients but is associated

182 nar we critically appraise the management of Hodgkin's lymphoma in early-stage disease, advanced-stag

183 Although the association of non-Hodgkin's lymphoma in SLE is well established, risk fact

184 DLBCL is the most common non-Hodgkin's lymphoma in the adult population, accounting f

185 Subtypes of indolent non-Hodgkin's lymphoma included follicular lymphoma (72 pati

186 d antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.

187 Non-Hodgkin's lymphoma is a disseminated, highly malignant c

188 Non-Hodgkin's lymphoma is considered an AIDS-defining entity

189 ic, adolescent, and young adult survivors of Hodgkin's lymphoma is not known.

190 ic, adolescent, and young adult survivors of Hodgkin's lymphoma is reflected in the cumulative burden

191 nervous system relapse in patients with non-Hodgkin's lymphoma is, typically, an early event, occurs

192 As in clinical samples of EBV-associated non-Hodgkin's lymphomas is unknown.

193 Although NHL (non-Hodgkin's lymphoma) is the fifth leading cause of cancer

194 1-TR, active in nasopharyngeal carcinoma and Hodgkin's lymphoma, is located within the first of a hig

195 hich improves survival for patients with non-Hodgkin's lymphoma, is often withheld from elderly patie

196 cular lymphoma (FL), an incurable B cell non-Hodgkin's lymphoma, is thought to play a major role in i

197 tuberculosis), hematological malignancy (non-Hodgkin's lymphoma, leukemia), and renal failure (P </=

198 n of lytic virus replication in a B cell non-Hodgkin's lymphoma line by preventing expression of BZLF

199 V entry into the lytic cycle in a B cell non-Hodgkin's lymphoma line by upregulating the cellular tra

200 ment for early-stage, lymphocyte-predominant Hodgkin's lymphoma (LPHL) is not well defined.

201 ce changed in alternating directions for non-Hodgkin's lymphoma, melanoma, and lung, pancreatic, and

202 Patients with Hodgkin's lymphoma might have persistent fatigue even ye

203 NHL subtypes, malignant immunoproliferation, Hodgkin's lymphoma, multiple myeloma, and various leukae

204 ot associated with follicular or T-cell NHL, Hodgkin's lymphoma, multiple myeloma, or various leukaem

205 ymphoma (n = 43), polymorphic PTLD (n = 10), Hodgkin's lymphoma (n = 7), Burkitts lymphoma (n = 6), p

206 ew agent for the treatment of follicular non-Hodgkin's lymphoma (NHL) and also diffuse large B-cell l

207 eased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemi

208 SD symptoms among long-term survivors of non-Hodgkin's lymphoma (NHL) and identified demographic, cli

209 ients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) are older than 60 years, yet th

210 onal Comprehensive Cancer Network (NCCN) non-Hodgkin's lymphoma (NHL) database with a documented path

211 ociation of hepatitis C virus (HCV) with non-Hodgkin's lymphoma (NHL) has been demonstrated throughou

212 with younger children with mature B-cell non-Hodgkin's lymphoma (NHL) have been historically consider

213 autologous stem-cell transplantation in non-Hodgkin's lymphoma (NHL) patients.

214 osis induction in human Burkitt's B-cell non-Hodgkin's lymphoma (NHL) Raji cells as determined using

215 of bendamustine in patients with B-cell non-Hodgkin's lymphoma (NHL) refractory to rituximab.

216 TCL) are rare and heterogeneous forms of non-Hodgkin's lymphoma (NHL) that, in general, are associate

217 er (PTSD) symptoms in survivors of adult non-Hodgkin's lymphoma (NHL) who are at least 2 years postdi

218 owers the risk for melanomas, leukemias, non-Hodgkin's lymphoma (NHL), and ovarian cancer.

219 rmous progress has been made in treating non-Hodgkin's lymphoma (NHL), and some patients can be cured

220 hCD59 is highly expressed in B-cell non-Hodgkin's lymphoma (NHL), and upregulation of hCD59 is a

221 The bcl-2 gene is overexpressed in non-Hodgkin's lymphoma (NHL), such as small lymphocytic lymp

222 death from many malignancies, including non-Hodgkin's lymphoma (NHL).

223 vors of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).

224 es to higher cancer incidence, including non-Hodgkin's lymphoma (NHL).

225 th relapsed or refractory CD22(+) B-cell non-Hodgkin's lymphoma (NHL).

226 n, which may influence susceptibility to non-Hodgkin's lymphoma (NHL).

227 of single-agent lenalidomide in indolent non-Hodgkin's lymphoma (NHL).

228 n (aHCT) for Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).

229 suggested promising activity in indolent non-Hodgkin's lymphoma (NHL).

230 unotherapy is an effective treatment for non-Hodgkin's lymphoma (NHL).

231 standard of care for many patients with non-Hodgkin's lymphoma (NHL).

232 y of hematologic malignancies, including non-Hodgkin's lymphoma (NHL).

233 emia (CLL), Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL).

234 (HCV) infection has been associated with non-Hodgkin's lymphoma (NHL); however, the results are incon

235 sons have an elevated risk of developing non-Hodgkin's lymphoma (NHL); this risk remains increased in

236 mmon malignancies were NMSC (n = 11) and non-Hodgkin's lymphoma (NHL; n = 4) and malignancy risk was

237 stinct types of aggressive B- and T-cell non-Hodgkin's lymphomas (NHLs).

238 mphoid leukaemias, acute myeloid leukaemias, Hodgkin's lymphomas, non-Hodgkin lymphomas, astrocytomas

239 Non-Hodgkin's lymphoma occurred at a rate 7.6 times that of

240 remarkable advances in the treatment of non-Hodgkin's lymphoma of all histologic subtypes, nervous s

241 ymphoma (CTCL), a heterogeneous group of non-Hodgkin's lymphomas of skin-homing T cells.

242 ncers included: Hodgkin's lymphoma (13), non-Hodgkin's lymphoma (one), pinealoblastoma (one), tongue

243 assigned to ABVD alone, 6 patients died from Hodgkin's lymphoma or an early treatment complication an

244 tologically confirmed relapsed or refractory Hodgkin's lymphoma or anaplastic large-T-cell lymphoma,

245 radiation therapy, 4 deaths were related to Hodgkin's lymphoma or early toxic effects from the treat

246 sis for those who develop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma.

247 r treatment-naive patients with indolent non-Hodgkin's lymphoma or mantle cell lymphoma.

248 whose primary childhood cancer diagnosis was Hodgkin's lymphoma or sarcoma and who received radiother

249 Outcome of multiply relapsed Hodgkin's lymphoma patients treated with single-dose bre

250 translation studies involving six confirmed Hodgkin's lymphoma patients, two suspicious lymphoma cas

251 of choice for primary refractory or relapsed Hodgkin's lymphoma patients.

252 s with newly diagnosed stage IA or stage IIA Hodgkin's lymphoma received three cycles of ABVD and the

253 Patients with non-Hodgkin's lymphoma requiring an autologous hematopoietic

254 nical studies in a murine model of human non-Hodgkin's lymphoma showed cancer cells eradication and l

255 o preceding fatigue and age, patient sex and Hodgkin's lymphoma specific risk factors at baseline did

256 igue in patients with Hodgkin's lymphoma and Hodgkin's lymphoma survivors and could inform developmen

257 Outcomes in the Hodgkin's lymphoma survivors were compared with a sample

258 In this large cohort of Hodgkin's lymphoma survivors with long follow-up, we est

259 ce of severe acute and persistent fatigue in Hodgkin's lymphoma survivors, which is largely independe

260 ural and internal mammary lymphadenopathy in Hodgkin's lymphoma than in sarcoidosis.

261 a (MCL) is a rare and aggressive form of non-Hodgkin's lymphoma that generally affects older individu

262 udy, 23 patients with relapsed or refractory Hodgkin's lymphoma that had already been heavily treated

263 -cell lymphoma (CTCL) is a heterogeneous non-Hodgkin's lymphoma that may variably involve the skin, l

264 showed expression of vIL-10 transcripts in a Hodgkin's lymphoma that was uncoupled from lytic genes.

265 represent a spectrum of several distinct non-Hodgkin's lymphomas that are characterized by an invasio

266 in many composite non-Hodgkin lymphomas and Hodgkin's lymphomas, the tumours are clonally related.

267 ith disease progression, 1 of whom died from Hodgkin's lymphoma); there had been 20 instances of dise

268 observed across all subtypes of indolent non-Hodgkin's lymphoma, though the numbers were small for so

269 DG PET/CT for monitoring the response of non-Hodgkin's lymphoma to radioimmunotherapy.

270 reviously untreated stage IA or IIA nonbulky Hodgkin's lymphoma to treatment with doxorubicin, bleomy

271 me 6q21 associated with SMNs in survivors of Hodgkin's lymphoma treated with radiation therapy as chi

272 + months occurred in three patients with non-Hodgkin's lymphoma, two patients with hormone- and docet

273 tients with newly diagnosed advanced classic Hodgkin's lymphoma underwent a baseline PET-CT scan, rec

274 tients with sarcoidosis and 37 patients with Hodgkin's lymphoma using the International Association f

275 se vs stable disease) and primary refractory Hodgkin's lymphoma versus relapsed disease less than 12

276 population in England, whereas the rate for Hodgkin's lymphoma was 5.9 times.

277 The risk of non-Hodgkin's lymphoma was not associated with malathion use

278 opsy specimens from patients with B-cell non-Hodgkin's lymphoma, we observed a significantly low freq

279 of the colon, soft tissue, melanoma, and non-Hodgkin's lymphoma were significantly higher among cervi

280 They are traditionally divided into Hodgkin's lymphoma (which accounts for about 10% of all

281 sion lymphoma (PEL) is a rare subtype of non-Hodgkin's lymphoma, which is associated with infection b

282 imary mediastinal large B-cell lymphomas and Hodgkin's lymphomas, which depend on c-Rel for survival,

283 nrolled patients with relapsed or refractory Hodgkin's lymphoma who had failed one previous doxorubic

284 (aged >/=18 years) with recurrent classical Hodgkin's lymphoma who had failed to respond to autologo

285 treatment-naive, CD30-positive patients with Hodgkin's lymphoma who had histologically confirmed stag

286 safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior trea

287 -risk relapsed or primary refractory classic Hodgkin's lymphoma who had undergone autologous stem-cel

288 ved for patients with relapsed or refractory Hodgkin's lymphoma who previously received an autologous

289 le safety profile in patients with classical Hodgkin's lymphoma who progressed after autologous stem-

290 ical outcomes in 33 patients with B-cell non-Hodgkin's lymphoma who received post-transplantation rit

291 hase 2 study, 125 patients with indolent non-Hodgkin's lymphomas who had not had a response to rituxi

292 in the bone marrow, and one patient with non-Hodgkin's lymphoma with a p53 splice site mutation showe

293 l lymphoma (MCL) is an aggressive B-cell non-Hodgkin's lymphoma with a poor prognosis.

294 b, and CD180) for potential treatment of non-Hodgkin's lymphoma with ADCs.

295 ion was attributable to an increased risk of Hodgkin's lymphoma with NNRTIs (HR = 2.20; 95% CI, 1.03

296 ma (PTCL) is a poor prognosis subtype of non-Hodgkin's lymphoma with no accepted standard of care.

297 d progression-free survival in patients with Hodgkin's lymphoma with risk factors for relapse or prog

298 have shown a significant association of non-Hodgkin's lymphoma with SLE.

299 ients with relapsed and refractory classical Hodgkin's lymphoma, with an acceptable safety profile.

300 chanism shared by common forms of B-cell non-Hodgkin's lymphoma, with direct implications for the use